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Highly active antiretroviral therapy (HAART) reduces the incidence and improves the prognosis of Kaposi’s sarcoma (KS). This study
was designed to identify factors associated with KS clinical responses in HIV-infected patients during HAART. We reviewed the files
of 138 HIV-1-infected patients with KS. Epidemiologic and HIV-related clinical and biological parameters were recorded at KS
diagnosis (baseline) and every 6 months thereafter. In a subset of 73 antiretroviral-naive patients, we compared the clinical outcome
of KS according to the use or nonuse of protease inhibitors (PI). After 6 months of follow-up, KS remission was more frequent in
patients who were naive of HAART and who were at ACTG stage S0 at baseline (P¼0.03 and 0.02). Undetectable HIV viral load
was strongly associated with KS remission (Pp0.004 at all time points), while CD4 cell count was not. Among the 73 antiretroviral-
naive patients at baseline, and who were studied for 24 months, KS outcome did not differ between patients who were prescribed PI-
containing and PI-sparing regimens. Intercurrent multicentric Castleman’s disease was associated with poor outcome after 60 months
of follow-up (Pp0.0001). Fourteen deaths occurred after a median follow-up of 37.5 months, eight of which were KS related.
Suppression of HIV replication appears to be crucial to control KS. Non-PI-based regimens were equivalent to PI-based regimens as
regards the clinical and virological outcome of antiretroviral-naive HIV-infected patients with KS.
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Kaposi’s sarcoma (KS) has remained the most common AIDS-
associated malignancy since the beginning of the HIV/AIDS
pandemic (Brodt et al, 1997). The introduction of highly active
antiretroviral therapy (HAART) in 1996 was associated with
undetectable HIV plasma viral load in most patients, together with
increased CD4 cell counts, increased survival, and fewer oppor-
tunistic infections and AIDS-associated malignancies (Li et al,
1998; Palella et al, 1998; Levine and Tulpule, 2001). Most studies
have shown that KS improves during protease inhibitor (PI)-based
antiretroviral treatment, an effect variously attributed to modula-
tion of Tat and of production of HIV cytokines, restoration of
specific anti-human herpesvirus type 8 (HHV-8) immunity, or the
antiangiogenic and antiproliferative effect of PIs (Krischer et al,
1998; Lebbe et al, 1998; Cattelan et al, 1999, 2001; Paparizos et al,
2002; Leitch et al, 2003). The impact of HAART on immune
responses to HHV-8, the main aetiologic agent of KS and
multicentric Castleman’s disease, is poorly understood. Kaposi’s
sarcoma lesions are characterised by neoangiogenesis and
proliferation of spindle cells of endothelial origin, including cells
of lymphatic lineage (Dupin et al, 1999). Although experimental
studies have shown that PI may have specific antiangiogenic and
antiproliferative properties, their specific impact on the clinical
outcome of KS has been discussed (Sgadari et al, 2002, 2003).
Complete remission of KS has been reported in patients receiving
PI, and also relapses after switching to NNRTI-based regimens
(Murdaca et al, 2002; Bani-Sadr et al, 2003). In contrast, a
significantly lower incidence of KS was observed in HIV-infected
patients receiving an NNRTI-based regimen than in those
receiving a PI-based regimen in a cohort of 8640 patients
(Portsmouth et al, 2003). Moreover, NNRTI are also as effective
as PIs in prolonging time to treatment failure in KS (Bower et al,
1999).
The antiangiogenic action of PI makes these drugs the treatment
of choice for HIV-infected patients with KS. However, the so-called
PI-sparing regimens are equivalent to PI-based regimens as
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sregards HIV control, while they have better observance and
fewer adverse effects (Bucher et al, 2003). In order to compare
the impact of PI-based and non-PI-based antiretroviral regimens
on KS, we reviewed the epidemiological and clinical characteristics
and outcome of 138 HIV-1-infected, HAART-treated patients
with KS. We also sought factors predictive with KS progression
during HAART, analysed the outcome of KS according to CD4
cell count and HIV-1 plasma viral load variations, and compared
the benefits of PI and non-PI-based regimens on KS in a sub-
group of patients who had not previously received antiretroviral
drugs.
PATIENTS AND METHODS
This retrospective study was conducted in the Department of
Infectious Diseases and the Department of Dermatology of two
hospitals in Paris, France. Patients were eligible for the study if
they had HIV-1 infection and KS, and received HAART before
or at the time of KS diagnosis. The time of KS diagnosis was
considered as coming on study. Kaposi’s sarcoma had to be
diagnosed between January 1996 (corresponding to widespread
introduction of HAART in France) and May 2001. Protease
inhibitor drugs were available in France since January 1996
whereas regimen with NNRTI since 1998. According to their
respective availability and international recommandations, triple
NRTI or NNRTI-based therapy were thus more likely to be recently
prescribed than PI-based therapy. Patients with other neoplasms
and those with HHV-8 disease diagnosed before January 1996 were
not eligible for the study. The following epidemiological and
clinical data were recorded at the time of KS diagnosis (baseline):
age, gender, HIV risk group, known duration of HIV infection, the
ACTG stage of KS (Krown et al, 1997), specific chemotherapy for
KS, and associated multicentric Castleman disease. Central, east,
west Africa, southern Italy and south America were considered
as endemic countries for HHV-8 infection. The occurrence of
opportunistic infections or death, and immunologic and virologic
parameters of HIV infection (CD4 cell count and HIV-1 plasma
viral load) were recorded at baseline and at 6-month intervals
throughout follow-up, for outcome of HHV-8-associated
malignancies too. HIV plasma viral load was considered
undetectable if below 200 copies per millilitre. Specific cytotoxic
therapy for KS was used in a part of the patients and included:
combination of doxorubicin, daunorubicin, bleomycin, vinblas-
tine, liposomal anthracycline or paclitaxel, monotherapy
of bleomycin or vinblastine, IFN-alpha, beta-HCG or local
therapy.
In a subgroup of 73 patients who were antiretroviral naive at
baseline, we compared the outcome of KS according to the use or
non use of PI. Patients were treated and evaluated every 6 months
until 24 months under the same combination of antiretroviral
drugs. The choice of HAART was left to the patients’ individual
physicians. ‘KS remission’ refers to partial or complete remission
as defined in ACTG study (Krown et al, 1997), and ‘KS
progression’ refers to stable disease, progressive lesions or death
related to KS.
The patient’s characteristics were recorded as counts or
percentages for categorical variables, and medians and ranges
for continuous variables. Categorical variables were compared
between patients by using the w
2 test or Fisher’s exact test, as
appropriate. Continuous variables were compared using Mann–
Whitney test. Differences between groups were considered
significant if Pp0.05. A multivariate logistic regression model
was used to identify independent predictive factor for KS
remission at 6 months by including in the model all the variables
which were statistically significant or tended to be in univariate
analysis (Po0.1). Statistical analysis used the SPSS 11.5 program
(Chicago, IL, USA).
RESULTS
Baseline characteristics of the patients
We selected and included in this study 138 HIV-1-infected patients
from the clinical databases of the two participating units with KS,
including five with multicentric Castleman’s disease. The baseline
characteristics of the 138 patients are shown in Table 1. Median
age was 44 years (range 27–73 years). They were 135 men, of
whom 101 were homosexual. Kaposi’s sarcoma was the first AIDS-
defining disease in 43 patients. The 95 other patients were defined
as having AIDS according to the CDC classification, before the
diagnosis of KS. Thirty-seven patients had already had one or
more AIDS-defining events at the onset of KS (nine cytomegalo-
virus infection, nine atypical mycobacteriosis, eight cerebral
toxoplasmosis, five pneumocystosis, six herpes simplex virus
infection, three tuberculosis, three non-Hodgkin’s lymphoma, two
cryptococcosis and one multifocal progressive leukoencephalitis).
Forty-one (29.7%) patients originated from a country where HHV-
8 is endemic.
At KS diagnosis the median CD4 cell count was 68mm
 3 (range
0–797) and the median HIV-1 viral load was 176000 copiesml
 1
(range 199–2831000) in the whole group. The ACTG stages were
predominantly T0, I1 and S1. Sixty-five patients were already
receiving HAART and 73 patients had never received antiretroviral
therapy when KS was diagnosed but began HAART at this time.
In the subgroup of naive patients, the median CD4 cell count was
72mm
 3 (range 0–797) and the median HIV-1 viral load was
225235 copiesml
 1 (range 3870–2831000) whereas in patients
Table 1 Baseline characteristics of the 138 HIV-infected patients with
Kaposi’s sarcoma
Baseline characteristics Number of patients %
Gender
Male 135 97.8
Female 3 2.2
Multicentric Castleman’s disease 5 3.6
Patients from HHV-8-endemic countries 41 29.7
HIV exposure group
Homosexual 101 73.2
Heterosexual 33 23.9
Intravenous drug users 4 2.9
ACTG TIS classification
79 57.2
T0 59 42.8
T1 37 26.8
I0 101 73.2
I1 49 35.5
S0 89 64.5
S1
AIDS before KS diagnosis 95 68.8
Opportunistic infections at KS diagnosis 37 26.8
Ongoing HAART at KS diagnosis
Yes 65 47.1
No 73 52.9
Median Range
Age (years) 44 27–73
CD4 cell counts (per mm
3) 68 0–797
HIV viral load (copiesml
 1)
a 176000 199–2831000
an¼101.
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salready receiving HAART, the corresponding figures were
66mm
 3 (range 0–500) and 140000 copiesml
 1 (range 199–
747000). Plasma viral load was significantly higher (P¼0.004) in
naive patients than in patients previously treated by HAART
whereas CD4 cell counts did not differ (P¼0.88) between the two
groups. For patients already receiving HAART regimen at KS
diagnosis, the median duration of HAART was 33 weeks (range
16–98). Highly active antiretroviral therapy consisted of combina-
tions of three NRTI (n¼17), or two NRTI plus one NNRTI
(n¼12), or two NRTI plus one or two PI (n¼109) and was chosen
by each physician.
KS treatment and outcome
Seventy-two patients with KS received specific chemotherapy
including: adriamycin, bleomycin and vinblastine in 33 cases,
paclitaxel in two cases, daunorubicin in two cases, other
combinations of drugs in five cases, monotherapy of bleomycin
in 17 cases and of vinblastine in six cases, IFN-alpha in three cases,
local therapy in three cases and beta-HCG in one case for the first
6 months after diagnosis. Of the 73 naive patients, 40 (55%)
underwent a specific chemotherapy and 32 of the 65 (49%) patients
previously treated by HAART. The use or not of specific cytotoxic
drugs for KS had no impact on the evolution of KS in patients who
were already receiving antiretroviral therapy at baseline (P¼0.32)
and in naive patients (P¼0.59 comparing PI and non-PI-contain-
ing regimen). Nevertheless, the use of cytotoxic agents was left at
the discretion of the treating physician according to the
localisation and extension of the disease. Only five patients were
still receiving specific therapy for KS 24 months after diagnosis.
The percentage of patients in remission from KS increased during
follow-up, from 51% at 6 months to 62% at 12 months, 70% at 18
months and 76% at 24 months. After a median follow-up of 37.5
months (range 6–60 months), 14 patients (10%) had died, of
HHV-8 malignancies in eight cases (four with both KS and
multicentric Castleman’s disease) and of opportunistic infections
in six cases.
Factors predictive of KS outcome in the HAART era
Patients who were antiretroviral naive and those with KS stage S0
at baseline had a significantly higher chance of KS remission
during the first 6 months of follow-up (P¼0.03 and 0.02,
respectively) (Table 2). Moreover, in the 73 naive patients, there
was a trend to KS remission for patients with stage T0 (P¼0.08)
and stage S0 (P¼0.07). We also observed a significative trend to
remission when AIDS was diagnosed at the time of KS diagnosis
(P¼0.07). Nearly half of the patients developed KS while receiving
HAART. This goes counter to the popular wisdom that patients on
HAART rarely develop KS. These HAART-experienced patients
developed KS at a time when their HIV viral load was poorly
controlled (n¼61) and despite HIV suppression under the level of
detection for only four patients. During the first 6 months, KS was
in remission in 60.3% of 73 antiretroviral-naive patients, compared
to 41.5% of 65 patients who were already receiving antiretroviral
therapy at baseline. A highly significant relationship was found
between KS remission and undetectable HIV plasma viral load
during follow-up (P¼0.04 at month 6, Pp0.0001 at month 24,
P¼0.001 at months 48 and 60) (Figure 1). This relationship was
not observed for CD4 cell count (Figure 1). Multicentric Castle-
man’s disease was associated with KS in five patients, and was
associated with poor outcome (Pp0.0001): four patients had
died, and one had progressed after 60 months of follow-up. In
multivariate analysis only stage S remained significant: a stage S0
patient at baseline has 2.4 (CI 95%: 1.2–5.0) more chance of KS
remission during the first 6 months of follow-up than a stage S1
patient. The fact of being antiretroviral naive did not remain
significant (P¼0.07) in the multivariate analysis.
The 73 patients who were antiretroviral naive at baseline
remained on the same HAART regimen for at least 24 months.
Fifty-four patients were treated with PI-containing regimens and
19 did not received PI. At baseline, the ACTG stage distribution
(P¼0.46 for stage T, P¼0.7 for stage S and P¼0.47 for stage I),
CD4 cell counts (median 55mm
 3 for non-PI group vs 76mm
 3
Table 2 Risk factors for remission at 6 months according to baseline
characteristics: univariate and multivariate analysis
Remission (n¼71)
Univariate analysis
Multivariate
analysis
Risk factor (no. of
patients)
No. of
patients % P value
a OR CI 95%
Age (years)
p44 (71) 34 47.9 0.39
444 (67) 37 55.2
Sex
Men (135) 70 51.9 0.52
Women (3) 1 33.3
HIV exposure group
Homosexual (101) 52 51.5 0.37
b
Heterosexual (33) 19 57.6
Intravenous drug
user (4)
00
HHV-8 endemic country of
origin
Yes (41) 20 48.8 0.68
No (97) 51 52.6
Opportunistic infection at
KS diagnosis
Yes (37) 17 45.9 0.43
No (101) 54 53.5
AIDS revelated by KS
Yes (43) 27 62.8 0.07
No (95) 44 46.3
Antiretroviral naive at
baseline
Yes (73) 44 60.3 0.03
No (65) 27 41.5
T stage
T0 (79) 45 57 0.13
T1 (59) 26 44.1
I stage
I0 (37) 21 56.8 0.45
I1 (101) 50 49.5
S stage
S0 (49) 32 65.3 0.02 2.4 [1.2–5.0]
S1 (89) 39 43.8 1 (ref
c)
CD4 cell counts
o200mm
 3 (100) 50 50 0.58
X200mm
 3 (38) 21 55.3
HIV-1 plasma viral load
p200 copiesml
 1 (5) 3 60 0.83
4200 copiesml
 1 (96) 53 55.2
aDetermined with w
2 Pearson (Fisher’s exact test for ‘sex’).
bWithout including IDU.
cReference.
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sfor PI group), and HIV plasma viral load (median 204000
copiesml
 1 for non-PI group vs 275000 copiesml
 1 for PI group)
were not statistically different between the two groups (P¼0.2 and
0.1 for CD4 cell counts and viral load, respectively) and were not
significantly related to KS remission at 6 months. During the 24
months of follow-up, the KS remission rate was not significantly
different between the two groups (Figure 2): there was no evidence
for a better outcome in the patients receiving a PI-containing
regimen (Figure 2).
DISCUSSION
We examined clinical and biological factors associated with KS
remission in HIV-1-infected patients receiving HAART. In multi-
variate analysis, only ACTG KS stage S0 was associated with KS
remission at month 6. Intercurrent multicentric Castleman’s
disease was associated with poor vital outcome and with KS
progression. Undetectable HIV-1 plasma viral load was the best
predictor of KS remission, independently of the CD4 cell count.
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Figure 2 Efficacy of PI-based regimens (white box) and non-PI-based
regimens (black box) on KS in 73 HIV-infected antiretroviral-naive patients.
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sIn our study, specific chemotherapy in addition to HAART had no
impact on KS outcome. Finally, among patients who were
antiretroviral naive at baseline, KS outcome was similar in those
who received PI- and non-PI-based regimens.
HIV-1 interacts strongly with HHV-8. The HIV Tat protein,
which is released by infected cells, regulates many viral and host
functions. It stimulates the growth of KS lesions by stimulating the
proliferation of spindle cells, activating cytokine genes (e.g. IL-6)
and inhibiting IFN-g-mediated apoptosis (Boshoff et al, 1995;
Nicholas et al, 1997; Deregibus et al, 2002). The Tat gene has a
direct angiogenic effect by interacting with several receptors, and
also enhances HHV-8 infectivity (Albini et al, 1995; Aoki and
Tosato, 2004). Uncontrolled HIV replication is associated with
progression of HHV-8 malignancies (Nicholas et al, 1997; Brodt
et al, 1998). As in previous studies, we found that suppression of
HIV replication was crucial for controlling KS (Albini et al, 1995;
Boshoff et al, 1995; Nicholas et al, 1997; Barillari and Ensoli, 2002;
Deregibus et al, 2002).
The influence of the CD4 cell count on KS outcome is
controversial. Two studies have shown a correlation between KS
remission and a high CD4 cell count or a strong increase in the
CD4 cell count. Dupont et al (2000) found that an increase in the
CD4 cell count of more than 150 10
6l
 1 after 12 months of
HAART was predictive of complete remission from KS at month 24
in HIV-infected patients. Similarly, Cattelan et al (1999) found a
positive correlation between the CD4 cell count and KS control
during antiretroviral therapy. In contrast, like us, Nasti et al
(2003a,b) found that HIV suppression was associated with good
KS outcomes, independently of immune restoration reflected by
the CD4 cell count. Undetectable HIV-1 plasma viral load thus
appears to be the best predictor of KS remission, independently of
the CD4 cell count.
In our subgroup of patients who had not previously received
antiretroviral drugs, PI-based regimens and PI-sparing regimens
were similarly effective in terms of KS remission. Protease
inhibitors can affect important cellular processes such as
angiogenesis, tumor growth and invasion, inflammation, antigen
processing and presentation, cell survival, tissue remodelling and
metastasis (Sgadari et al, 2003). Protease inhibitors have direct
antiproliferative and antiangiogenic effects in vitro, and inhibit the
development of KS-like lesions in animal models by blocking an
enzyme required for the production of infectious HHV-8 particles
(Pati et al, 2002; Sgadari et al, 2002, 2003). In clinical trials,
PI-containing regimens led to full remission from KS in
approximately 50% of patients, and conferred an added survival
benefit (Burdick et al, 1997; Aboulafia, 1998; Krischer et al, 1998;
Cattelan et al, 1999; De Milito et al, 1999; Paparizos et al, 2002;
Leitch et al, 2003; Sgadari et al, 2003).
In contrast, the impact of NNRTI-based regimens on KS is
controversial (Murdaca et al, 2002; Bani-Sadr et al, 2003; Ports-
mouth et al, 2003). Both complete remissions with NNRTI and
relapses of KS in patients switching from PI- to NNRTI-based
regimens have been described (Murdaca et al, 2002; Bani-Sadr
et al, 2003). Two prospective studies showed that PI were not
essential to clear HHV-8 DNA (Gill et al, 2002; Bourboulia et al,
2004). Similarly, Stebbing et al (2004) showed that NNRTI-based
HAART regimens were not inferior to PI-based regimens in
preventing KS. NNRTI-containing antiretroviral regimens are
as effective as PI-based regimens on HIV infection, but are
associated with better adherence, fewer adverse effects, and similar
immune restoration (Bucher et al, 2003; Pozniak et al, 2003).
However, PI-containing regimens are superior to NNRTI combi-
nations including nevirapine or delavirdine in patients with
advanced immunodepression and previous exposure to NRTI
(Yazdanpanah et al, 2004). Our results, together with previous
reports, suggest that KS regression in this setting is mediated by an
overall improvement in immune function, modulation of cytokine
expression, and control of HIV and HHV-8 replication, rather than
by a direct specific antiangiogenic effect of antiretroviral therapy.
It is noteworthy that the effects of NRTI and NNRTI on
angiogenesis and proliferation have not been studied. However,
we found that PI-sparing regimens were as effective as PI-based
regimens in term of KS outcome in antiretroviral-naive HIV-
infected patients.
Our patients who were antiretroviral naive at baseline had an
increased chance of KS remission during the first 6 months of
HAART in the univariate analysis. This might be due to partial
recovery of anti-HHV-8 immune function, probable infection by
wild-type HIV strains and a presumed better adherence compared
to previously HAART-treated patients. Nevertheless, paradoxical
transient deterioration have been described in KS patients, as seen
in patients with tuberculosis and other opportunistic infections
(Narita et al, 1998; Baril et al, 2000; Stone et al, 2002). Shelburne
et al (2005) showed that patients who have been antiretroviral
naive at time of diagnosis of their opportunistic infection have
an increased risk of immune inflammatory syndrome. Also,
Bourboulia et al (2004) reported that anti-HHV-8 immune recon-
stitution only occurred after more than 24 months of HAART, and
that this contributed to the fall in the KS incidence during
antiretroviral treatment. Early KS progression (within the first
months following HAART introduction) may thus mimic immune
reconstitution (Bower et al, 2005).
In conclusion, patients with ACTG KS stage S0 at baseline have
an increased chance of remission of HHV-8 malignancies during
the first six months of HAART. Patients with both KS and
multicentric Castleman’s disease have a particularly poor prog-
nosis. Suppression of HIV replication by HAART appears to be the
key factor in KS control, independently of the CD4 cell count.
NNRTI- and NRTI-based regimens appear to be equivalent to PI-
based regimens in terms of clinical and virological outcome in
antiretroviral-naive HIV-infected patients with KS. It thus seems
necessary to define more precisely, in clinical trials, the interest of
specific anti-KS drugs on the evolution of KS in HAART era
whereas PI- and NNRTI-based regimen seem to have similar
efficiency on KS outcome.
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